Oral Presentation to Include Interim Results from its Ongoing Phase 1/2 BMN 270 Clinical Program, a Gene Therapy for Hemophilia A.
Conference call and web-cast to be held July 11th at 2:30pm CEST/8:30am ET

http://investors.biomarin.com/2017-06-16-BioMarin-Announces-Acceptance-of-Late-Breaking-Abstract-at-the-International-Society-on-Thrombosis-and-Haemostasis-2017-Congress

Share this story, choose your platform!